FOR IMMEDIATE RELEASE
February 21, 2017

Pfizer Japan Inc.
Eisai Co., Ltd.

APPROVAL RECEIVED FOR PAIN TREATMENT
LYRICA® OD TABLET FORMULATION IN JAPAN

Pfizer Japan Inc. (Headquarters: Tokyo, President and Representative Director: Ichiro Umeda,”Pfizer”) announced today that it received marketing and manufacturing approval in Japan on February 17 for Lyrica® OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin).

Lyrica Capsules are co-promoted in Japan by Pfizer and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) with both companies working to provide information on its proper use. Likewise, Lyrica OD Tablets will be co-promoted by both companies in Japan.

Lyrica OD Tablets are swiftly disintegrated by saliva inside the mouth, making it an easy form for elderly patients to take.

One of the indications for Lyrica is neuropathic pain, which is pain caused by any condition that results in compressed or dysfunctional nerves. Representative examples include postherpetic neuralgia, pain associated with diabetic neuropathy, sciatic neuralgia, and pain from spinal cord injury. Many of the patients who exhibit these symptoms are elderly, and Lyrica OD Tablets are expected to increase convenience when taking medicine.

Through Lyrica, Pfizer and Eisai will continue to contribute to improvement of quality of life in patients suffering from neuropathic pain and pain associated with fibromyalgia.

Media Inquiries:
Pfizer Japan Inc. Corporate Communications
Telephone: 03-5309-6644

Eisai Co., Ltd. PR Department
Telephone: 03-3817-5120
### Pain Treatment Lyrica OD Tablets Outline

<table>
<thead>
<tr>
<th><strong>Product Name:</strong></th>
<th>Lyrica® OD Tablet 25mg·75mg·150mg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Generic Name:</strong></td>
<td>pregabalin</td>
</tr>
<tr>
<td><strong>Date of Approval:</strong></td>
<td>February 17, 2017</td>
</tr>
<tr>
<td><strong>Manufactured and Marketed by:</strong></td>
<td>Pfizer Japan Inc.</td>
</tr>
<tr>
<td><strong>Co-promoted by:</strong></td>
<td>Eisai Co., Ltd.</td>
</tr>
<tr>
<td><strong>Indications and Usage</strong></td>
<td>Neuropathic pain, Pain associated with fibromyalgia</td>
</tr>
</tbody>
</table>

**Dosage and Administration**

**Neuropathic pain**
The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more. Dosage should be adjusted, depending on age and symptoms. However, the maximum daily dose should not be beyond 600 mg and should be orally administered twice daily.

**Pain associated with fibromyalgia**
The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as need. Dosage should be adjusted, depending on age and symptoms. However, the maximum daily dose should not be beyond 450 mg and should be orally administered twice daily.